Nucleic Acid Amplification Testing Market by Applications (Infectious Diseases [Virus, Bacteria, and Others], Cancer, Personalized Medicine, and Genetic & Mitochondrial Disorders), Technique (Target Amplification Systems, Probe Amplification Systems, and Signal Amplification), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global nucleic acid amplification testing market size is expected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising demand for advanced diagnostic measures and increased expenditures in the development of novel biotechnology diagnostic procedures. Furthermore, the rising incidence of infectious diseases linked to vectors such as bacteria and viruses is also boosting the overall market growth.
 

The nucleic acid amplification test (NAAT) is primarily conducted to detect some particular components and vectors including nucleic acid, bacteria or virus, which acts as a pathogen causing several diseases. The test involves an examining of biological samples such as blood, urine, and tissues to identify the presence of foreign vectors. Sample collection and nucleic acid (NA) extraction, target NA amplification, and target amplicon NA detection are the three main phases involved in a nucleic acid test. The NAAT involves an amplification stage for genetic material amplification and technique such as polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription-mediated assay (TMA) amplification of particular N. gonorrhoeae DNA or RNA sequences. NAATs can vary in terms of the required equipment and infrastructure, pre-amplification sample processing, reaction temperature, time to result, ease of use, detection limit, and cost. All tests, however, follow a similar procedure for their execution.

Since the outbreak of the COVID-19 pandemic, NAAT technique is employed for the diagnosis of SARS-CoV-2. The technique helps in the identification of the ribonucleic acid (RNA) sequences, which act as a favorable component for the virus growth. If any virus genetic material is found in a patient’s samples, the NAAT technique first identify it by amplifying or creating numerous copies of it. The technique also can identify extremely small levels of SARS-CoV-2 RNA in a sample because those nucleic acids are amplified, making them very sensitive for diagnosing COVID-19. NAATs have been approved for the use of various settings including laboratory facilities and Point-of-Care (POC) settings. Some NAATs can be performed at home or in other non-medical settings.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of communicable diseases such as SARS-CoV-2 and other infectious illness is projected to boost the market growth during the forecast period.
• Increased government initiatives encouraging to develop and employ these tests in various screening programs to detect the vectors is projected to boost the market growth.
• High accuracy of diagnosis and gradual development of advanced testing technology for the identification of diseases are projected to boost the market growth during the forecast period.
• Lack of expertise handling the testing procedures and inadequate healthcare infrastructure in emerging countries possess major challenging factors that can hamper the market growth during the forecast period.
• Extensive emphasis on R&D programs for identifying of various applications of NAAT in fields such as cancer, personalized medicine, and forensics is expected to offer significant opportunities for the market players.

Scope of the Report

The report on the global nucleic acid amplification testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Infectious diseases segment is expected to account for a key market share
Based on applications, the nucleic acid amplification testing market is segmented into infectious diseases, cancer, personalized medicine, and genetic & mitochondrial disorders. The infectious diseases segment is further sub segmented into virus, bacteria, and others. The infectious diseases segment is expected to account for a key share of the market during the forecast period owing to the high usage of NAAT for the detection of disease-causing bacteria and viral agents. On the other hand, the cancer segment is anticipated to expand at a rapid pace during the forecast period owing to high prevalence of cancer cases and rising demand for methods for early detection of various cancer types globally.

Target amplification system segment is expected to expand at a significant pace
In terms of technique, the market is divided into target amplification systems, probe amplification systems, and signal amplification. The target amplification system segment is expected to constitute a key share of the market during the forecast period owing to increased use of PCR technology because of its easy operations and high efficiency. Moreover, the segment growth can be attributed to the rising demand for diagnostics devices such as PCR techniques for COVID-19 virus.
 

North America segment is anticipated to expand at a substantial CAGR
On the basis of regions, the nucleic acid amplification testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to presence of a large number of players, a well-developed healthcare system, high disposable income, and favorable reimbursement policies.

On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing due to presence of fast-growing economies and favorable demographics, and other key factors such as the high prevalence of infectious diseases, and rising adoption of the advanced diagnostic technologies. Positive government initiative to implement NAT is also attributed to propel the regional market growth.
 

Segments

Segments Covered in the Report
The global nucleic acid amplification testing market has been segmented on the basis of

Applications

• Infectious Diseases
  • Virus
  • Bacteria
  • Others
• Cancer
• Personalized Medicine
• Genetic & Mitochondrial Disorders

Technique

• Target Amplification Systems
• Probe Amplification Systems
• Signal Amplification

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• Beckman Coulter, Inc.
• Abbott Laboratories, Inc.
• Illumina, Inc.
• Siemens Healthineers
• bioMérieux SA
• Novartis AG
• Bio-Rad Laboratories, Inc.

Competitive Landscape

Key players competing in the nucleic acid amplification testing market are F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Beckman Coulter, Inc.; Abbott Laboratories, Inc.; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; and Bio-Rad Laboratories, Inc.

This market is highly competitive, with only a few major companies controlling the market revenue share. To maintain their market expansion, these companies are focusing on new product development and research activities. Many of these companies are widely engaged for geographical expansion, which is considered to be one of the best business strategies to remain competitive in the market.